Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 812-724-1 | CAS number: 106705-37-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Epidemiological data
Administrative data
- Endpoint:
- epidemiological data
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- other: Any kind of reliability rating is not considered to be applicable, since human epidemiological studies, field studies and case reports are not conducted/reported according to standardised guidelines
- Rationale for reliability incl. deficiencies:
- other: Reliability rating according to Klimisch is not applicable for studies in humans.
Data source
Reference
- Reference Type:
- publication
- Title:
- Effects of oral supplementation with stable strontium
- Author:
- Skoryna, S.
- Year:
- 1 981
- Bibliographic source:
- Can. Med. Assoc. J. 125: 703-712.
Materials and methods
- Study type:
- cross sectional study
- Endpoint addressed:
- repeated dose toxicity: oral
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Clinical studies began by determining strontium and calcium levels in 100 subjects who were receiving a regular diet that supplied approximately 1 g of calcium and 1 to 2 mg of strontium a day. Then, 0.1 to 1.5 g/d of strontium gluconate (183 to 274 mg strontium) were administered for periods of at least 3 months to 50 of these patients with various conditions that might be affected by stable strontium: metastatic bone carcinoma, cachexia, postmenopausal osteoporosis and hepatic cholestasis. Parameters measured were as follows: mean serum levels of strontium and calcium and strontium:calcium ratio in serum.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- strontium gluconate
- IUPAC Name:
- strontium gluconate
- Test material form:
- not specified
- Details on test material:
- - Name of test material (as cited in study report): strontium gluconate
Constituent 1
Method
- Type of population:
- general
- Ethical approval:
- not specified
- Details on study design:
- The clinical studies began by determining strontium and calcium levels in 100 subjects who were receiving a regular diet that supplied approximately 1 g of calcium and 1 to 2 mg of strontium a day. Then, 0.1 to 1.5 g/d of strontium gluconate (183 to 274 mg strontium) were administered for periods of at least 3 months to 50 of these patients with various conditions that might be affected by stable strontium: metastatic bone carcinoma, cachexia, postmenopausal osteoporosis and hepatic cholestasis. Parameters measured were as follows: mean serum levels of strontium and calcium and strontium:calcium ratio in serum.
- Exposure assessment:
- not specified
- Details on exposure:
- no data
- Statistical methods:
- mean ± SD
Results and discussion
- Results:
- The mean serum levels of strontium and calcium and strontium:calcium ratio in serum of the 100 subjects taking a normal diet were as follows:
strontium: 0.0053 ± 0.0039 mg/dL
calcium: 9.432 ± 0.55 mg/dL
strontium:calcium ratio: 1:2247
The mean level of strontium in the serum of the 50 patients receiving 0.1 to 1.5 g/d strontium gluconate increased, while the calcium level did not change significantly as can be seen below.
strontium: 0.5128 ± 0.198 mg/dL
calcium: 9.449 ± 0.96 mg/dL
strontium:calcium ratio: 1:18
Furthermore, no side effects or toxic reactions were oberved, and 73 % of the patients gained an average of 2 kg of body weight over 2 to 3 months. Subjective feelings of improvement, which are impossible to evaluate, particularly in cancer patients, were frequently reported. In patients with metastatic bone cancer arising from a primary lesion in the breast or prostate, roentgenographic studies showed mineralization of metastatic lesions. Also a sclerotic halo occurred around some of the osteolytic metastatic lesions in the pelvis. - Confounding factors:
- no data
- Strengths and weaknesses:
- no data
Any other information on results incl. tables
ADDITIONAL FINDINGS:
A single oral dose of 0.5 g of strontium gluconate administered to a fasting subject resulted in a marked increase in the serum strontium concentration, with peak being reached in 4 hours; the level decreased rapidly in the next 72 hours, and then gradually over a 4 -week period. The level of calcium in the serum of this patient was 9.7 mg/dL before the strontium was given and 9.4 mg/dL 72 hours later.
Applicant's summary and conclusion
- Conclusions:
- According to the author, in patients receiving 1 to 1.5 g/d of strontium gluconate, a sustained increase in the serum level of strontium produced a 100-fold increase in the strontium:calcium ratio. Furthermore, an increase in density that corresponded to the deposition of stable strontium was observed in areas of bone lesions due to metastatic cancer in patients receiving stable strontium supplementation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.